Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Eos Neuroscience Inc
Profile last edited on: 2/6/13      CAGE: 4XF26      UEI:

Business Identifier: genetically targeted neurotherapeutics
Year Founded
2007
First Award
2009
Latest Award
2012
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

901 Mission Street Suite 105
San Francisco, CA 94103
   (310) 867-3368
   info@eosneuroscience.com
   www.eosneuroscience.com
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

Eos Neuroscience is developing developing novel treatments for blindness and other serious neurological conditions using optogenetic and gene therapy approaches. The firm also operates a laboratory in Los Angeles, CA.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$992,203
Phase II Dollars
$86,311
Total Awarded
$1,078,514

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2012 1 NIH $295,772
Project Title: Optimization Of An Optogenetic-Based Vision Therapy For Retinitis Pigmentosa
2011 1 NIH $394,442
Project Title: Development Of An Optical Silencer Based Genetic Therapy For Neuropathic Pain
2010 1 NIH $388,300
Project Title: Establishing Channelrhodopsin As A Tool To Restore Visual Function
0 1 NIH $301,989
Project Title: Establishing channelrhodopsin as a tool to restore visual function

Key People / Management

  Alan Greenberg

  William W Hauswirth

  Alan Horsager

Company News

There are no news available.